EPIDEMIOLOGY SURVEY, RESULTS FROM THE ARGENTINE MYELODYSPLASTIC SYNDROME REGISTRY. MDS STUDY GROUP OF THE ARGENTINE SOCIETY OF HEMATOLOGY

FLORES, GABRIELA; BELLI, CAROLINA; GONZALEZ, JACQUELINE; PRATES, M VIRGINIA; BASQUIERA, ANA L; ARBELBIDE, JORGE; NUCIFORA, ELSA; CABREJO, MARÍA; PINTOS, NOEMÍ; FERNANDEZ, VANESA; ALFONSO, GRACIELA; ENRICO, ALICIA; SANTOS, ISABEL; GARCÍA RIVELLO, HERNÁN; CRISP, RENÉE; NARBAITZ, MARINA; ROSENHAIN, MARIANA; KORNBLIHTT, LAURA; IASTREBNER, MARCELO

Milan

Congreso; 19th Congress of the European Haematology Association; 2014

EHA

Little is known about the incidence and epidemiological patterns of Myelodysplastic Syndromes (MDS) in Latin American region. The requirement of high quality exchangeable data has become a priority all over the world. Aims: To register MDS cases reported in our region, to review and analyze the data. Methods: From January 2007 through February 2014, fourteen Argentine Hematology Centers reported 479 adult patients (pts). FAB and WHO classification were taken into account, as well as IPSS, WPSS, and IPSS-R. Informed Consent was required. Results: Median age was 71 (range: 17-94), women 206 (43%), M/F ratio: 1.3, primary MDS (p-MDS) 425 (89%). FAB (422 evaluable pts), subtypes: RA 56%, RARS 7%, RAEB 17%, RAEB-T 6% and CMML 15% (Proliferative CMML 34%). WHO (355 pts): RCUD/RS 9%, 5q- 4%, RCMD 61%, RAEB-1 10%, and RAEB-2 16%. Median follow-up: 17 months, median OS: 43 months; deaths: 182 (40%), and Acute Myeloid Leukemia progression: 93 (19%). Prognostic Scoring Systems Results IPSS (n=352) L (43%), Int-1 (40%), Int-2 (12%), H (5%) WPSS (n=308) VL (29%), L (41%), I (22%), H + VH (8%) IPSS-R (n=345) VL (29%), L (40%), I (11%), H (11%), VH (8%) Cytogenetic in p-MDS according to IPSS-R (377 pts) showed: VL 3%, L 76%, IM 13%, H 4% and VH 4%, and the percentage of altered cytogenetic studies in secondary MDS (s-MDS) was 46%. Myelofibrosis (MF) was evaluated in 374 pts: MF0+MF1 (88%) and MF2+MF3 (12%), with a median survival of 47 and 16 months, respectively (p=0,004). Treatment reported: EPO (43%), iron chelation (4%), hypometilanting agents (27%), and Bone Marrow Transplant (3%). Summary/Conclusion: Although Argentine Registry is young with a relatively short follow-up, we were able to observe a high incidence of RA, CMML and a predominance of lower risk groups. There was a good correlation among different Scoring Systems, MDS subtypes and time to AML progression. In s-MDS, the number of altered cytogenetic studies was relatively low. The presence of Myelofibrosis was useful to predict survival. Erythropoietin and Hypomethylating agents were frequently used.